Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2009

View Archived Issues

Takeda divulges novel tachykinin NK2 receptor antagonists

Novel p110alpha inhibitors with anticancer activity developed at Roche

Solvay claims novel cannabinoid CB1 receptor agonists for use as analgesic agents

Novel inhibitors of bacterial DNA gyrase and/or topoisomerase type 4 prepared and tested

Pfizer imparts MMP-13 inhibitors for the treatment of osteoarthritis

Richter-Helm and Athera sign agreement for development of recombinant protein in ACS

PharmaSurgics receives Swedish approval to initiate phase I clinical program for PXL-01

Joslin to initiate clinical trial of antiinflammatory salsalate in type 2 diabetes

Lytix raises USD 10.4 million to fund clinical development of LTX-109 and LTX-315

Meritage initiates phase IIb clinical trial of oral viscous budesonide in pediatric patients

Fenobam safe, affects behavior in patients with Fragile X syndrome

Splice-switching oligonucleotide induces RNA repair in model of beta-thalassemia

Cladribine significantly reduced relapse rate of MS in phase III pivotal trial

CONFIRM 1 trial for voclosporin-coated coronary stent system fully enrolled

GSK's pediatric pneumococcal candidate vaccine receives positive opinion

MabThera receives positive E.U. opinion for first-line treatment of CLL

DiaKine reports results from preclinical mouse study of lisofylline in type 2 diabetes

Lexicon restructures operations to direct resources towards core therapeutic areas

FDA approves Geron's IND for phase I clinical trial of GRNOPC-1 in spinal cord injury

Cobra and Scancell sign GMP agreement for SCIB-1 DNA cancer vaccine

GSK acquires UCB's product portfolio across certain territories for EUR 515 million

European Commission withdraws marketing authorization for Roche's Zenapax

Alnylam receives FDA clearance to initiate phase I ALN-VSP study

Glenmark files phase I trial application with MHPRA for GRC-15300

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...